Merck & Co., Inc. $MRK Stock Position Increased by Partners Wealth Management LLC

Partners Wealth Management LLC grew its holdings in Merck & Co., Inc. (NYSE:MRK) by 176.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,506 shares of the company’s stock after buying an additional 5,427 shares during the quarter. Partners Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $1,243,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Bullseye Investment Management LLC acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at about $27,000. Curry Webb Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. during the 3rd quarter worth about $29,000. Horizons Wealth Management acquired a new position in shares of Merck & Co., Inc. during the 3rd quarter worth about $30,000. Graney & King LLC raised its position in shares of Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after purchasing an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC purchased a new position in Merck & Co., Inc. in the 2nd quarter valued at about $41,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the sale, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares in the company, valued at approximately $6,073,631.14. This trade represents a 63.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 in the last ninety days. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $149.75 on Friday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The firm’s 50-day moving average is $146.90 and its two-hundred day moving average is $126.69. Merck & Co., Inc. has a 12 month low of $82.01 and a 12 month high of $156.92. The company has a market capitalization of $369.46 billion, a PE ratio of 154.38, a price-to-earnings-growth ratio of 6.38 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.56%. The company had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. During the same period in the previous year, the business posted $2.58 EPS. Merck & Co., Inc.’s revenue was up 4.7% on a year-over-year basis. Analysts predict that Merck & Co., Inc. will post 2.80 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRK has been the topic of several research analyst reports. BMO Capital Markets lifted their price objective on Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, August 20th. Argus raised their target price on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Berenberg Bank lifted their target price on shares of Merck & Co., Inc. from $127.00 to $137.00 and gave the stock a “hold” rating in a research note on Friday, September 11th. Sanford C. Bernstein upped their price objective on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the company a “market perform” rating in a research note on Tuesday, August 4th. Finally, Morgan Stanley dropped their price target on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research report on Wednesday, October 7th. Seventeen equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $156.08.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.